Incretin Atlas › Trials › SYNERGY-NASH
SYNERGY-NASH
Tirzepatide · MASH F2–F3
Design
- Molecule(s)
- Tirzepatide
- Population
- MASH F2–F3
- Official title
- A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)
- Sponsor
- Eli Lilly and Company
- Phase
- Phase 2
- Registry status
- completed · 2019-11 → 2023-12
- Participants
- 190
- Duration
- 52 weeks
- Registry
- NCT04166773
Outcomes in the indication
SYNERGY-NASH Tirzepatide · MASH F2–F3 · 52 weeks · n = 190 seed
MASH resolution without worsening fibrosis 44–62 % vs 10 %
| Measure | Drug | Control | Difference (95 % CI) | Status |
|---|---|---|---|---|
| MASH resolution without worsening of fibrosis - tirzepatide 10 mg 10 mg week 52 | +56.0 | +10.0 | +46.0 (+29.0 to +62.0) percentage points | verified |
| MASH resolution without worsening of fibrosis - tirzepatide 15 mg 15 mg week 52 | +62.0 | +10.0 | +53.0 (+37.0 to +69.0) percentage points | verified |
| MASH resolution without worsening of fibrosis - tirzepatide 5 mg 5 mg week 52 | +44.0 | +10.0 | +34.0 (+17.0 to +50.0) percentage points | verified |
Verbatim quotes (3)
- MASH resolution without worsening of fibrosis - tirzepatide 10 mg
56% in the 10-mg tirzepatide group (difference, 46 percentage points; 95% CI, 29 to 62)
- MASH resolution without worsening of fibrosis - tirzepatide 15 mg
62% in the 15-mg tirzepatide group (difference, 53 percentage points; 95% CI, 37 to 69)
- MASH resolution without worsening of fibrosis - tirzepatide 5 mg
44% in the 5-mg tirzepatide group (difference vs. placebo, 34 percentage points; 95% confidence interval [CI], 17 to 50)
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: SYNERGY-NASH. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/synergy-nash/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.